160 related articles for article (PubMed ID: 12653922)
1. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
Lowe NJ; Gonzalez J; Bagel J; Caro I; Ellis CN; Menter A
Int J Dermatol; 2003 Mar; 42(3):224-30. PubMed ID: 12653922
[TBL] [Abstract][Full Text] [Related]
2. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.
Krueger GG
J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():17-24. PubMed ID: 12795771
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
[TBL] [Abstract][Full Text] [Related]
4. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
6. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
Ortonne JP
J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
[TBL] [Abstract][Full Text] [Related]
8. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
[TBL] [Abstract][Full Text] [Related]
9. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
10. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
11. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
[TBL] [Abstract][Full Text] [Related]
12. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Gribetz CH; Blum R; Brady C; Cohen S; Lebwohl M
J Am Acad Dermatol; 2005 Jul; 53(1):73-5. PubMed ID: 15965424
[TBL] [Abstract][Full Text] [Related]
13. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
Feldman SR; Menter A; Koo JY
Br J Dermatol; 2004 Feb; 150(2):317-26. PubMed ID: 14996104
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN; Krueger GG;
N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.
Cafardi JA; Cantrell W; Wang W; Elmets CA; Elewski BE
Skinmed; 2008; 7(2):67-72. PubMed ID: 18327010
[TBL] [Abstract][Full Text] [Related]
17. Development and use of alefacept to treat psoriasis.
Krueger GG; Callis KP
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
19. Alefacept.
Frampton J; Wagstaff A
Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
[TBL] [Abstract][Full Text] [Related]
20. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
